Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study

Bo Björkstrand; Thomas Rasmussen; Kari Remes; Astrid Gruber; Tarja-Terttu Pelliniemi; Hans E. Johnsen

doi:10.1034/j.1600-0609.2003.00068.x

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study

European Journal Of Haematology ◽

10.1034/j.1600-0609.2003.00068.x ◽

2003 ◽

Vol 70 (6) ◽

pp. 379-383 ◽

Cited By ~ 6

Author(s):

Bo Björkstrand ◽

Thomas Rasmussen ◽

Kari Remes ◽

Astrid Gruber ◽

Tarja-Terttu Pelliniemi ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study

Download Full-text

Faculty Opinions recommendation of Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962446.793468191 ◽

2012 ◽

Author(s):

Steven Le Gouill ◽

Cyrille Touzeau

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study ◽

Randomized Phase Ii

Download Full-text

Phase II study of cyclophosphamide, interferon-α and betamethasone (CIB) as induction therapy for patients 60–75 years of age with multiple myeloma stages II and III

The Hematology Journal ◽

10.1038/sj.thj.6200301 ◽

2003 ◽

Vol 4 (4) ◽

pp. 248-252 ◽

Cited By ~ 6

Author(s):

Jeanette Lundin ◽

Anders Österborg ◽

Magnus Björkholm ◽

Bo Björkstrand ◽

Fredrik Celsing ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study ◽

Interferon Α

Download Full-text

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

British Journal of Haematology ◽

10.1111/bjh.14920 ◽

2017 ◽

Vol 179 (4) ◽

pp. 586-597 ◽

Cited By ~ 10

Author(s):

Hermann Einsele ◽

Monika Engelhardt ◽

Christoph Tapprich ◽

Jürgen Müller ◽

Peter Liebisch ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study

Download Full-text

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

Experimental Hematology and Oncology ◽

10.1186/s40164-018-0110-0 ◽

2018 ◽

Vol 7 (1) ◽

Cited By ~ 4

Author(s):

Henrik Gregersen ◽

Trung Do ◽

Ida Bruun Kristensen ◽

Ulf Christian Frølund ◽

Niels Frost Andersen ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study ◽

High Dose ◽

Newly Diagnosed ◽

Stem Cell Support ◽

High Dose Melphalan ◽

Cell Support

Download Full-text

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Case Medical Research ◽

10.31525/ct1-nct03839446 ◽

2000 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Phase Ii ◽

Induction Therapy ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

Gemtuzumab Ozogamicin ◽

Acute Myeloid

Download Full-text

Randomized Phase II Study of Bortezomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Multiple Myeloma.

Case Medical Research ◽

10.31525/ct1-nct04277845 ◽

2020 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii

Download Full-text

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Case Medical Research ◽

10.31525/ct1-nct04302324 ◽

2020 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Phase Ii Study

Download Full-text

Faculty Opinions recommendation of Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718500080.793522210 ◽

2016 ◽

Author(s):

Parameswaran Hari ◽

Binod Dhakal

Keyword(s):

Multiple Myeloma ◽

Phase Ii ◽

Phase Ii Study ◽

Front Line ◽

Transplantation Program

Download Full-text

Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features

Current Problems in Cancer ◽

10.1016/j.currproblcancer.2021.100788 ◽

2021 ◽

pp. 100788

Author(s):

Kwai Han Yoo ◽

Dok Hyun Yoon ◽

Hye Jin Kang ◽

Won Sik Lee ◽

Kihyun Kim ◽

...

Keyword(s):

Multiple Myeloma ◽

High Risk ◽

Phase Ii ◽

Phase Ii Study ◽

Newly Diagnosed ◽

Multicenter Phase

Download Full-text

Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study

Medical Oncology ◽

10.1007/s12032-018-1172-x ◽

2018 ◽

Vol 35 (7) ◽

Cited By ~ 1

Author(s):

Koji Nishimoto ◽

Masato Karayama ◽

Naoki Inui ◽

Hideki Yasui ◽

Hironao Hozumi ◽

...

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Induction Therapy ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

Switch Maintenance Therapy

Download Full-text